ESR2 and breast cancer: Interestingly, when LINC00052 expression is inhibited, ‘Pro-oncogenic action of estradiol_estrogen receptors’ as well as ‘ESR1/ESR2 ratio in breast cancer’ signalling pathways are modulated [20].